Last reviewed · How we verify
NCT02332551
Percutaneous Irreversible Electroporation to Treat Liver Cancer Close to the Gallbladder
NA trial testing NanoKnife in Hepatic Carcinoma in 30 participants. Completed in 1 August 2021.
1 December 2020
Quick facts
| Lead sponsor | Fuda Cancer Hospital, Guangzhou |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | single |
| Primary purpose | treatment |
| Enrollment | 30 |
| Start date | 1 January 2015 |
| Primary completion | 1 December 2020 |
| Estimated completion | 1 August 2021 |
| Sites | 1 location across China |
Drugs / interventions tested
- NanoKnife
Conditions studied
- Hepatic Carcinoma — all drugs for Hepatic Carcinoma →
Sponsor
Fuda Cancer Hospital, Guangzhou
Who can join
Adults 18 to 75, any sex, with Hepatic Carcinoma. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The purpose of this study is to investigate the safety and efficacy of irreversible electroporation for unresectable Hepatic carcinoma close to the gallbladder, also Progress Free Survival (PFS) will be recorded.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Combination of natural killer cell-based immunotherapy and irreversible electroporation for the treatment of hepatocellular carcinoma.
Eresen A, Yang J, Scotti A, Cai K, et al · · 2021 · cited 14× · PMID 34423001 · DOI 10.21037/atm-21-539
Verify or expand the search:
- PubMed search for NCT02332551
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of NanoKnife
Trials testing the same drug.
- NCT06937996 — Outcomes of Ablation of Unresectable Pancreatic Cancer Using the NanoKnife Irreversible Electroporation System- · recruiting
- NCT02430675 — Irreversible Electroporation(IRE) For Unresectable Laryngeal Neoplasms · NA · completed
- NCT02430597 — Irreversible Electroporation(IRE) For Unresectable Hilus Pulmonis Neoplasms · NA · completed
- NCT02430779 — Irreversible Electroporation(IRE) For Unresectable Renal Pelvic and Ureteral Neoplasms · NA · completed
- NCT02335112 — Irreversible Electroporation(IRE) For Unresectable Head and Neck Neoplasms · NA · completed
Other recruiting trials for Hepatic Carcinoma
Currently open trials in the same condition.
- NCT07359586 — Laryngopharyngeal Injury After Endotracheal Intubation Under General Anesthesia · recruiting
- NCT06342414 — An Exosome-Based Liquid Biopsy for the Differential Diagnosis of Primary Liver Cancer · recruiting
- NCT04220944 — Combined Locoregional Treatment With Immunotherapy for Unresectable HCC. · Phase 1 · active not recruiting
Other Fuda Cancer Hospital, Guangzhou trials
Trials by the same sponsor.
- NCT04393220 — Combination of PD-1 and VEGFR-2 Blockade for Advanced Hepatocellular Carcinoma · Phase 2 · completed
- NCT03673137 — Phase II/III of Randomized Controlled Clinical Research on IRE Synchronous Chemotherapy for LAPC · Phase 2, PHASE3 · completed
- NCT03976206 — Very Small Embryonic-like Stem Cells for Facial Skin Antiaging · Phase 1, PHASE2 · withdrawn
- NCT03975101 — Very Small Embryonic-like Stem Cells for Knee Osteoarthritis · Phase 1, PHASE2 · withdrawn
- NCT03985462 — Very Small Embryonic-like Stem Cells for Ovary · Phase 1, PHASE2 · withdrawn
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT02332551 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Fuda Cancer Hospital, Guangzhou
- Last refreshed: 5 September 2021
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02332551.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing